Key Takeaway: Werewolf Therapeutics has announced that its investigational drug WTX-124 has received Fast Track Designation from the FDA. This designation is aimed at facilitating the development of therapies for serious conditions, specifically targeting advanced or metastatic solid tumors. The Fast Track status may accelerate the drug's review process, enhancing its availability to patients.
Price reaction · baseline $2.23 (2025-09-29T14:56:00.000Z) · hit during market hours · clean, no other HOWL news in the window
day 0 close · peak
-1.8%
Market Sentiment Analysis
POSITIVE FACTORS
FDA Fast Track Designation granted for WTX-124
Targeting advanced or metastatic solid tumors
Potential for expedited development and review
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
September 29, 2025
Werewolf Therapeutics Receives FDA Fast Track Designation for WTX-124 for the Treatment of Advanced or Metastatic Solid Tumors
WATERTOWN, Mass., September 29, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”).
Share this article:
facebook-icon
twitter-icon
linked-in-icon
Frequently Asked Questions
What is WTX-124?
WTX-124 is an investigational drug developed by Werewolf Therapeutics targeting advanced or metastatic solid tumors.
What does FDA Fast Track Designation mean?
FDA Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs for serious conditions.
What types of tumors does WTX-124 target?
WTX-124 is aimed at treating advanced or metastatic solid tumors.
When was the Fast Track Designation granted?
The Fast Track Designation for WTX-124 was granted on September 29, 2025.